ResMed Inc. (RMD) on Decifer

Decifer ranks RMD number 75 of 268 tracked names on durable business quality.

Why it ranks here

• Sales are growing about 10% a year, faster than 42 in 100 companies we measure.
• It keeps about 29 cents of every sales dollar as cash, safer than 92 in 100 companies we measure.
• It earns about 20% a year on the money put into the business, better than 86 in 100 companies we measure.
• It costs about 24 times its yearly profit; the middle of its industry is 52. Cheaper than 90 in 100 companies we measure, against their own industries.

The current read

The evidence on RMD lines up on the supportive side: the intelligence feed flags this name as connected to what is moving markets now. The independent signals we track are telling the same story.

Themes

• GLP-1 & Metabolic Disease Wave: GLP-1 receptor agonists have demonstrated large-scale efficacy in obesity and diabetes, triggering a multi-hundred-billion-dollar demand and capex surge across pharma and diabetes-device makers.

Read the full RMD research brief · See all quality rankings

Intelligence data powered by Decifer. Not financial advice. For informational purposes only.